60 YEARS OF NEUROENDOCRINOLOGY: Biology of human craniopharyngioma: lessons from mouse models.
暂无分享,去创建一个
[1] F. Saggioro,et al. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas. , 2015, European journal of endocrinology.
[2] C. Swanton,et al. Can oncology recapitulate paleontology? Lessons from species extinctions , 2015, Nature Reviews Clinical Oncology.
[3] J. Martinez-Barbera,et al. Molecular and cellular pathogenesis of adamantinomatous craniopharyngioma , 2015, Neuropathology and applied neurobiology.
[4] Charles Swanton,et al. Translational Implications of Tumor Heterogeneity , 2015, Clinical Cancer Research.
[5] A. Grossman,et al. The Wnt Signalling Cascade and the Adherens Junction Complex in Craniopharyngioma Tumorigenesis , 2015, Endocrine Pathology.
[6] N. McGranahan,et al. Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. , 2015, Cancer cell.
[7] R. Fahlbusch,et al. Insights into the Infiltrative Behavior of Adamantinomatous Craniopharyngioma in a New Xenotransplant Mouse Model , 2015, Brain pathology.
[8] C. Eaves,et al. Hierarchical organization of fetal and adult hematopoietic stem cells. , 2014, Experimental cell research.
[9] V. Sondak,et al. Beyond BRAF: where next for melanoma therapy? , 2014, British Journal of Cancer.
[10] Pieter Wesseling,et al. International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading , 2014, Brain pathology.
[11] G. Long,et al. Systemic treatment for BRAF-mutant melanoma: where do we go next? , 2014, The Lancet. Oncology.
[12] M. He,et al. Fetal Craniopharyngioma: Management, Postmortem Diagnosis, and Literature Review of an Intracranial Tumor Detected in Utero , 2014, Pediatric and developmental pathology : the official journal of the Society for Pediatric Pathology and the Paediatric Pathology Society.
[13] Michael Kahn,et al. Can we safely target the WNT pathway? , 2014, Nature Reviews Drug Discovery.
[14] A. Salajegheh,et al. BRAF inhibitors: From the laboratory to clinical trials. , 2014, Critical reviews in oncology/hematology.
[15] Yanyan Hu,et al. Pituitary stalk interruption syndrome in 59 children: the value of MRI in assessment of pituitary functions , 2014, European Journal of Pediatrics.
[16] A. Grossman,et al. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma , 2014, Acta Neuropathologica.
[17] N. Karavitaki. Management of craniopharyngiomas , 2014, Journal of Endocrinological Investigation.
[18] H. Müller. Childhood craniopharyngioma: treatment strategies and outcomes , 2014, Expert review of neurotherapeutics.
[19] R. Rabadán,et al. Leukemogenesis Induced by an Activating β-catenin mutation in Osteoblasts , 2014, Nature.
[20] M. Ghert,et al. Lost in translation: animal models and clinical trials in cancer treatment. , 2014, American journal of translational research.
[21] John Y. K. Lee,et al. Exome sequencing identifies BRAF mutations in papillary craniopharyngiomas , 2014, Nature Genetics.
[22] F. Saran,et al. Radiotherapy in craniopharyngiomas. , 2013, Clinical oncology (Royal College of Radiologists (Great Britain)).
[23] M. Dattani,et al. Sox2(+) stem/progenitor cells in the adult mouse pituitary support organ homeostasis and have tumor-inducing potential. , 2013, Cell stem cell.
[24] Yun-Bo Shi,et al. Global expression profiling reveals genetic programs underlying the developmental divergence between mouse and human embryogenesis , 2013, BMC Genomics.
[25] L. Bystrykh,et al. Heterogeneity of young and aged murine hematopoietic stem cells revealed by quantitative clonal analysis using cellular barcoding. , 2013, Blood.
[26] J. Eloy,et al. Molecular oncogenesis of craniopharyngioma: current and future strategies for the development of targeted therapies. , 2013, Journal of neurosurgery.
[27] A. Kulkarni,et al. Trends in treatment and outcomes of pediatric craniopharyngioma, 1975-2011. , 2013, Neuro-oncology.
[28] Darjus F. Tschaharganeh,et al. Non-Cell-Autonomous Tumor Suppression by p53 , 2013, Cell.
[29] D. Van Roost,et al. Treatment of Cystic Craniopharyngioma by Endocavitary Instillation of Yttrium90 Radioisotope—Still a Valuable Treatment Option , 2013, Journal of Neurological Surgery—Part A.
[30] O. Ansorge,et al. Pathology and pathogenesis of craniopharyngiomas , 2013, Pituitary.
[31] R. Moon,et al. WNT signalling pathways as therapeutic targets in cancer , 2012, Nature Reviews Cancer.
[32] C. You,et al. Intracystic bleomycin for cystic craniopharyngiomas in children (abridged republication of cochrane systematic review). , 2012, Neurosurgery.
[33] J. Wisoff. Commentary: intracystic bleomycin for cystic craniopharyngiomas in children (abridged republication of cochrane systematic review). , 2012, Neurosurgery.
[34] S. A. Jayakody,et al. SOX2 regulates the hypothalamic-pituitary axis at multiple levels. , 2012, The Journal of clinical investigation.
[35] J. Visvader,et al. Cancer stem cells: current status and evolving complexities. , 2012, Cell stem cell.
[36] S. Hettige,et al. Malignant transformation in craniopharyngiomas. , 2012, Neurosurgery.
[37] C. Begley,et al. Drug development: Raise standards for preclinical cancer research , 2012, Nature.
[38] J. Martinez-Barbera,et al. Identification of novel pathways involved in the pathogenesis of human adamantinomatous craniopharyngioma , 2012, Acta Neuropathologica.
[39] Peter Dirks,et al. Cancer stem cells: an evolving concept , 2012, Nature Reviews Cancer.
[40] J. Drake,et al. Intracystic Therapies for Cystic Craniopharyngioma in Childhood , 2011, Front. Endocrin..
[41] J. Hamilton,et al. Long Term Sequelae of Pediatric Craniopharyngioma – Literature Review and 20 Years of Experience , 2011, Front. Endocrin..
[42] J. Wesche,et al. Fibroblast growth factors and their receptors in cancer. , 2011, The Biochemical journal.
[43] K. Flaherty,et al. BRAF targeted therapy changes the treatment paradigm in melanoma , 2011, Nature Reviews Clinical Oncology.
[44] S. A. Jayakody,et al. Increased Wingless (Wnt) signaling in pituitary progenitor/stem cells gives rise to pituitary tumors in mice and humans , 2011, Proceedings of the National Academy of Sciences.
[45] I. Blümcke,et al. EGFR Signaling Regulates Tumor Cell Migration in Craniopharyngiomas , 2011, Clinical Cancer Research.
[46] S. Camper,et al. Birthdating studies reshape models for pituitary gland cell specification. , 2011, Developmental biology.
[47] P. Laurberg,et al. Incidence of craniopharyngioma in Denmark (n = 189) and estimated world incidence of craniopharyngioma in children and adults , 2011, Journal of Neuro-Oncology.
[48] A. Algra,et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials , 2010, The Lancet.
[49] H. Müller. Childhood craniopharyngioma—current concepts in diagnosis, therapy and follow-up , 2010, Nature Reviews Endocrinology.
[50] C. Fanali,et al. The role of inflammation in the genesis of the cystic component of craniopharyngiomas , 2010, Child's Nervous System.
[51] J. Lin,et al. Expression of aberrant β-catenin and impaired p63 in craniopharyngiomas , 2010, British journal of neurosurgery.
[52] H. Müller. Childhood craniopharyngioma: current controversies on management in diagnostics, treatment and follow-up , 2010, Expert review of neurotherapeutics.
[53] T. Merchant,et al. Radiation therapy for pediatric craniopharyngioma. , 2010, Neurosurgical focus.
[54] I. Blümcke,et al. Tumour cell migration in adamantinomatous craniopharyngiomas is promoted by activated Wnt-signalling , 2010, Acta Neuropathologica.
[55] T. Merchant,et al. Malignant transformation of irradiated craniopharyngioma in children: report of 2 cases. , 2010, Journal of neurosurgery. Pediatrics.
[56] Jeremy Stinson,et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. , 2009, The New England journal of medicine.
[57] I. Blümcke,et al. Target Gene Activation of the Wnt Signaling Pathway in Nuclear β‐Catenin Accumulating Cells of Adamantinomatous Craniopharyngiomas , 2009, Brain pathology.
[58] Raphael Kopan,et al. Epidermal Notch1 loss promotes skin tumorigenesis by impacting the stromal microenvironment. , 2009, Cancer cell.
[59] G. A. Gallego,et al. Biology of BMP signalling and cancer. , 2009 .
[60] M. Malumbres,et al. A GRFa2/Prop1/Stem (GPS) Cell Niche in the Pituitary , 2009, PloS one.
[61] S. Bilodeau,et al. Distinct Developmental Roles of Cell Cycle Inhibitors p57Kip2 and p27Kip1 Distinguish Pituitary Progenitor Cell Cycle Exit from Cell Cycle Reentry of Differentiated Cells , 2009, Molecular and Cellular Biology.
[62] R. Lovell-Badge,et al. SOX2-expressing progenitor cells generate all of the major cell types in the adult mouse pituitary gland , 2008, Proceedings of the National Academy of Sciences.
[63] J. V. van Dongen,et al. The human androgen receptor X-chromosome inactivation assay for clonality diagnostics of natural killer cell proliferations. , 2007, The Journal of molecular diagnostics : JMD.
[64] I. Blümcke,et al. Nuclear β-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas , 2007, Acta Neuropathologica.
[65] I. Blümcke,et al. Nuclear β-Catenin Accumulation as Reliable Marker for the Differentiation Between Cystic Craniopharyngiomas and Rathke Cleft Cysts: A Clinico-Pathologic Approach , 2006, The American journal of surgical pathology.
[66] C. Bolger,et al. Primary cerebellopontine angle craniopharyngioma in a patient with gardner syndrome. Case report and review of the literature. , 2006, Journal of neurosurgery.
[67] M. Rosenfeld,et al. Homeodomain-Mediated β-Catenin-Dependent Switching Events Dictate Cell-Lineage Determination , 2006, Cell.
[68] T. Merchant. Craniopharyngioma radiotherapy: endocrine and cognitive effects. , 2006, Journal of pediatric endocrinology & metabolism : JPEM.
[69] M. Buchfelder,et al. β-catenin mutations in craniopharyngiomas and pituitary adenomas , 2005, Journal of Neuro-Oncology.
[70] R. Fahlbusch,et al. Common mutations of β-catenin in adamantinomatous craniopharyngiomas but not in other tumours originating from the sellar region , 2005, Acta Neuropathologica.
[71] J. Warner,et al. Craniopharyngiomas in children and adults: systematic analysis of 121 cases with long‐term follow‐up , 2005, Clinical endocrinology.
[72] S. Hirohashi,et al. Expression of enamel proteins and LEF1 in adamantinomatous craniopharyngioma: evidence for its odontogenic epithelial differentiation , 2004, Histopathology.
[73] J. Squire,et al. Comparative genomic hybridization analysis of pediatric adamantinomatous craniopharyngiomas and a review of the literature. , 2004, Journal of neurosurgery.
[74] A. Emser,et al. Longitudinal study on growth and body mass index before and after diagnosis of childhood craniopharyngioma. , 2004, The Journal of clinical endocrinology and metabolism.
[75] K. Tachibana,et al. Possible linkage between specific histological structures and aberrant reactivation of the Wnt pathway in adamantinomatous craniopharyngioma , 2004, The Journal of pathology.
[76] M. Başkaya,et al. An Alternative Extradural Exposure to the Anterior Clinoid Process: The Superior Orbital Fissure as a Surgical Corridor , 2003, Neurosurgery.
[77] Hans Clevers,et al. Notch1 functions as a tumor suppressor in mouse skin , 2003, Nature Genetics.
[78] W. Paulus,et al. Lack of chromosomal imbalances in adamantinomatous and papillary craniopharyngiomas , 2003, Journal of neurology, neurosurgery, and psychiatry.
[79] S. Hirohashi,et al. Short Communication Craniopharyngiomas of Adamantinomatous Type Harbor -Catenin Gene Mutations , 2002 .
[80] E. Friedman,et al. Clonal composition of human adamantinomatous craniopharyngiomas and somatic mutation analyses of the patched (PTCH), Gsα and Gi2α genes , 2001, Neuroscience Letters.
[81] J. Bruner,et al. The descriptive epidemiology of craniopharyngioma. , 1998, Neurosurgical focus.
[82] Jörg Stappert,et al. β‐catenin is a target for the ubiquitin–proteasome pathway , 1997 .
[83] M. Choux,et al. Cytogenetic studies in 45 pediatric brain tumors. , 1992, Pediatric hematology and oncology.
[84] L. McMorrow,et al. Multiple chromosomal abnormalities in a case of craniopharyngioma. , 1992, Cancer genetics and cytogenetics.
[85] C. Griffin,et al. Chromosome abnormalities in low-grade central nervous system tumors. , 1992, Cancer genetics and cytogenetics.
[86] F. Gilles,et al. Cytogenetic analysis of 39 pediatric central nervous system tumors. , 1992, Cancer genetics and cytogenetics.
[87] R. Buslei,et al. Adamantinomatous craniopharyngioma: pathology, molecular genetics and mouse models , 2015, Journal of pediatric endocrinology & metabolism : JPEM.
[88] Chunde Li,et al. High expression levels of CXCL12 and CXCR4 predict recurrence of adamanti-nomatous craniopharyngiomas in children. , 2014, Cancer biomarkers : section A of Disease markers.
[89] E. Friedman,et al. Comparative genomic hybridization analysis of craniopharyngiomas. , 2003, Journal of neurosurgery.
[90] L. Abernethy. Imaging of the pituitary in children with growth disorders. , 1998, European journal of radiology.